


LISTING OF THE CLAIMS

The following listing of the claims reflects current amendments and replaces all previous listings.

1. (Currently amended) A compound of the formula



wherein Ar is selected from the group consisting of aryl, heteroaryl, benzoheteroaryl, pyridone, pyridazinone, and pyrimidone;

n is 1-6;

~~R₁ and R₂ are independently H, alkyl or aralkyl or R₁ and R₂ along with N can form a pyrrolidine, piperadine, piperazine, morpholine, benzopyrrolidine, benzopiperadine or benzopiperazine ring, or R₁ and L₁ or R₁ and one carbon of (CH₂)_n can form a 5, 6, or 7 membered ring;~~

R₃ is H, alkyl or aralkyl;

X and Y are independently is C or N;

Y is N;

~~R₄, R₅, and R₆ are independently is selected from the group consisting of H, alkyl, aralkyl, aryl, heteroaryl, benzoheteroaryl, hydroxyl, halo, haloalkyl, alkoxy, aminocarbonyl and aminosulfonyl; or~~


R₅ and R₆ together ~~can~~ form a 5-6 membered aromatic ring or a 5-7 membered aliphatic ring; L₁ is selected from the group consisting of ~~a single bond, O, NR₇, CO, and SO₂, NR₈CO, NR₉SO₂, NR₁₀CONR₁₁, NR₁₂SO₂NR₁₃, arene, heteroarene, pyridone, pyrimidone and pyridazinone;~~

~~L₂ and L₃ are independently selected from the group consisting of a single bond, CH₂, NR₁₄, CO and SO₂; and~~

R_7 - R_{14} are independently selected from the group consisting of H, alkyl, aryl and aralkyl or R_8 and CO and Ar can form pyridone, pyridazinone, and pyrimidone, ~~and the~~ or a pharmaceutically acceptable salts- salt thereof.

2. (Canceled).

3. (Currently amended) A compound of claim 1 of the formula:



wherein each R_{15} is independently H, alkyl, aralkyl, haloalkyl, aryl, heteroaryl, benzoheteroaryl, alkoxy, aminocarbonyl or aminosulfonyl and two of R_{15} can form a 5-6 membered aromatic ring or a 5-7 member aliphatic ring;

m is 0-3; and

R_1 , R_2 , R_4 , R_5 , R_6 , n and X are as defined in claim 1, ~~and the~~ or a pharmaceutically acceptable salts- salt thereof.

4. (Currently amended) A compound of claim 1 selected from the group consisting of: {4-Chloro-3-[2-(3,4-dihydro-1H-isoquinolin-2-yl)ethoxy]phenyl}-(2-methylquinolin-4-yl)amine;

{3-[2-(4-Benzylpiperidin-1-yl)ethoxy]phenyl}-(2-methylquinolin-4-yl)amine;

{4-Chloro-3-[2-(4-phenylpiperidin-1-yl)ethoxy]phenyl}-(2-methylquinolin-4-yl)amine;

{3-[2-(4-Benzylpiperazin-1-yl)ethoxy]phenyl}-(2-methylquinolin-4-yl)amine;

~~{3-[2-(Benzylmethylamino)ethoxy]phenyl}-(2-methylquinolin-4-yl)amine;~~

{3-[2-(4-Benzylpiperidin-1-yl)ethoxy]-5-trifluoromethylphenyl}-(2-methylquinolin-4-yl)amine;

{3-[3-(4-Benzylpiperidin-1-yl)propoxy]phenyl}-(2-methylquinolin-4-yl)amine;

~~{3-[2-(1-Methyl-1-phenylethylamino)ethoxy]phenyl}-(2-methylquinolin-4-yl)amine;~~

~~{3-(2-Benzylaminoethoxy)phenyl}-(2-methylquinolin-4-yl)amine;~~

1-(1-{2-[3-(2-Methylquinolin-4-ylamino)phenoxy]ethyl}4-phenylpiperidin-4-yl)ethanone;

~~{3-(3-Benzylaminopropoxy)phenyl}-(2-methylquinolin-4-yl)amine;~~

~~{3-[2-(2-Benzylimidazol-1-yl)ethoxy]phenyl}-(2-methylquinolin-4-yl)amine;~~
~~(1-{2-[3-(2-Methylquinolin-4-ylamino)phenoxy]ethyl}piperidin-4-yl)diphenylmethanol;~~
~~4-Benzyl-1-{2-[3-(2-tert-butylquinolin-4-ylamino)phenoxy]ethyl}piperidin-4-ol;~~
~~4-Benzyl-1-{2-[3-(2-methylquinolin-4-ylamino)-5-trifluoromethylphenoxy]ethyl}piperidin-4-ol;~~
~~{3-[2-(4-Benzylpiperidin-1-yl)ethoxy]phenyl}-(2,6-dimethylpyrimidin-4-yl)amine;~~
~~{3-[2-(5-Benzyl-2,5-diazabicyclo-[2.2.1]hept-2-yl)ethoxy]phenyl}-(2-methylquinolin-4-yl)amine;~~
~~{3-[2-(4-Benzylpiperazin-1-yl)ethoxy]-5-trifluoromethylphenyl}-(2-methylquinolin-4-yl)amine;~~
~~(2-Methylquinolin-4-yl)-{3-[2-(4-phenylpiperidin-1-yl)-ethoxy]-5-trifluoromethylphenyl}amine;~~
~~{3-[3-(1-Methyl-1-phenylethylamino)propoxy]phenyl}-(2-methylquinolin-4-yl)amine.~~
~~{3-[2-(5-Benzyl-2,5-diazabicyclo[2.2.1]hept-2-yl)ethoxy]-5-trifluoromethylphenyl}-(2-methylquinolin-4-yl)amine;~~
~~N-(2-{1-[2-(3-Fluorophenyl)ethyl]-6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl}ethyl)-3-(2-methylquinolin-4-ylamino)benzamide;~~
~~N-[2-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]-3-(2-methylquinolin-4-ylamino)benzamide;~~
~~N-[2-(1,3-Dihydroisoindol-2-yl)ethyl]-3-(2-methylquinolin-4-ylamino)benzamide;~~
~~N-[2-(3,4-Dihydro-1H-isoquinolin-2-yl)ethyl]-2-methyl-5-(2-methylquinolin-4-ylamino)benzamide;~~
~~N-[2-(3,4-Dihydro-1H-isoquinolin-2-yl)ethyl]-2-hydroxy-5-(2-methylquinolin-4-ylamino)benzamide;~~
~~N-[2-(3,4-Dihydro-1H-isoquinolin-2-yl)ethyl]-3-(2-trifluoromethylquinolin-4-ylamino)benzamide;~~
~~N-[2-(3,4-Dihydro-1H-isoquinolin-2-yl)ethyl]-2,4,6-trimethyl-3-(2-methylquinolin-4-ylamino)benzamide;~~
~~2-[2-(3,4-Dihydro-1H-isoquinolin-2-yl)ethyl]-4-(2-methylquinolin-4-ylamino)-2,3-dihydroisoindol-1-one;~~

~~3-(2-Methylquinolin-4-ylamino)-N-[2-(1,3,4,5-tetrahydrobenzo[c]azepin-2-yl)ethyl]benzamide;~~
~~N-[2-(3,4-Dihydro-1H-isoquinolin-2-yl)ethyl]-2,5-bis(2-methylquinolin-4-ylamino)benzamide;~~
~~3-(2-Methylquinolin-4-ylamino)-N-[2-(octahydro-eis-isoquinolin-2-yl)ethyl]benzamide;~~
~~N-(2-Azepan-1-ylethyl)-3-(2-methylquinolin-4-ylamino)benzamide;~~
~~N-(2-Benzylaminoethyl)-3-(2-methylquinolin-4-ylamino)benzamide;~~
~~4-((2-[3-(2-Methylquinolin-4-ylamino)-benzoylamino]ethylamino)methyl)benzoic acid;~~
~~N-[2-(2,2-Dimethylpropylamino)ethyl]-3-(2-methylquinolin-4-ylamino)benzamide;~~
~~N-[2-(4-Benzylpiperazin-1-yl)ethyl]-3-(2-methylquinolin-4-ylamino)benzenesulfonamide;~~
~~{3-[5-(3,4-Dihydro-1H-isoquinolin-2-ylmethyl)isoxazol-3-yl]phenyl}-(2-methylquinolin-4-yl)amine;~~
~~{3-[3-(3,4-Dihydro-1H-isoquinolin-2-yl)propyl]-4-methylphenyl}-(2-methylquinolin-4-yl)amine;~~
~~N'-[2-(3,4-Dihydro-1H-isoquinolin-2-yl)ethyl]-N⁷-(2-methylquinolin-4-yl)-1,2,3,4-tetrahydronaphthalene-1,7-diamine;~~
~~{3'-(3,4-Dihydro-1H-isoquinolin-2-ylmethyl)biphenyl-4-yl}-(2-methylquinolin-4-yl)amine;~~
~~{3-[2-(4-Benzylpiperidin-1-yl)ethanesulfonyl]phenyl}-(2-methylquinolin-4-yl)amine;~~
~~N-[2-(4-Benzylpiperidin-1-yl)ethyl]-N'-(2-methylquinolin-4-yl)pyrimidine-4,6-diamine; and~~
~~]3-(4-Benzylpiperidin-1-yl)-1-[3-(2-methylquinolin-4-ylamino)phenyl]propan-1-one oxime;~~

5. (Previously presented) A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier or excipient.

6. (Withdrawn) A method of treating conditions associated with urotensin-II imbalance by antagonizing the urotensin-II receptor which comprises administering to a patient in need thereof, a compound of claim 1.

7. (Withdrawn) A method according to claim 6 wherein the condition is selected from the group consisting of congestive heart failure, stroke, ischemic heart disease, angina, myocardial ischemia, cardiac arrhythmia, essential and pulmonary hypertension, renal disease, acute and chronic renal failure, end stage renal disease, peripheral vascular disease, male erectile dysfunction, diabetic retinopathy, intermittent claudication/ischemic limb disease,

USSN 10/783,916

Filed: February 20, 2004

Response and Amendment

ischemic/hemorrhagic stroke, COPD, restenosis, asthma, neurogenic inflammation, migraine, metabolic vasculopathies, bone/cartilage/joint diseases, arthritis and other inflammatory diseases, fibrosis, pulmonary fibrosis, sepsis, atherosclerosis, dyslipidemia, addiction, schizophrenia, cognitive disorders, Alzheimers disease, impulsivity, anxiety, stress, depression, Parkinsons, movement disorders, sleep-wake cycle, inventive motivation, pain, neuromuscular function, diabetes, gastric reflux, gastric motility disorders, ulcers and genitourinary diseases.